Clinically important upper GI bleeding · people admitted to intensive care units
Sucralfate probably leads to lower clinically important upper GI bleeding compared with placebo or no prophylaxis (moderate certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
Sucralfate showed no clear difference in nosocomial pneumonia compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
Sucralfate showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Duration of ICU stay · people admitted to intensive care units
1 finding from 1 review
Blood transfusion · people admitted to intensive care units
Sucralfate showed no clear difference in number of participants requiring blood transfusion compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean GI symptom scores · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acute and late GI toxicity (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
Summary of findings: Sucralfate showed no clear difference in acute and late GI toxicity (grade 2+) [acute = during RT; late = 6… compared with placebo (moderate certainty).
1 finding from 1 review
Diarrhoea (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
Summary of findings: Sucralfate may leads to lower diarrhoea (grade 2+) [during RT] compared with placebo (low certainty).
1 finding from 1 review
QoL · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Sucralfate versus nonadherent · people with venous leg ulcers
The intervention may leads to higher sucralfate versus nonadherent (low certainty).
1 finding from 1 review
RR 6.8 [2.24, 20.7]
Studies not reported
Low
Intervention not reported
Sucralfate versus foam · people with venous leg ulcers
The intervention may leads to higher sucralfate versus foam (low certainty).
1 finding from 1 review
RR 5.94 [1.96, 18]
Studies not reported
Low
Intervention not reported
Sucralfate versus hydrocolloid · people with venous leg ulcers
The intervention may leads to higher sucralfate versus hydrocolloid (low certainty).
1 finding from 1 review
RR 6.51 [2.17, 19.6]
Studies not reported
Low
Intervention not reported
Sucralfate versus silver · people with venous leg ulcers
It is very uncertain whether the intervention changes sucralfate versus silver (very low certainty).
1 finding from 1 review
RR 2.8 [0.88, 8.97]
Studies not reported
Very low
Clinically important upper GI bleeding · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in clinically important upper GI bleeding compared with sucralfate (low certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
H2 receptor antagonists probably leads to higher nosocomial pneumonia compared with sucralfate (moderate certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with sucralfate (low certainty).
1 finding from 1 review
Duration of ICU stay · people admitted to intensive care units
1 finding from 1 review
Blood transfusion · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in number of participants requiring blood transfusion compared with sucralfate (low certainty).
1 finding from 1 review
Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found